Actinium Pharmaceuticals
ATNM
37 hedge funds and large institutions have $13.7M invested in Actinium Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 3 reducing their positions, and 7 closing their positions.
479% more capital inflows, than outflows
Capital inflows: $3.97M | Capital outflows: $685K
400% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 3
308% more call options, than puts
Call options by funds: $2.81M | Put options by funds: $689K
1.09% less ownership
Funds ownership: 9.65% → 8.56% (-1.1%)
8% less funds holding
Funds holding: 40 → 37 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.94M |
| 2 |
State Street
Boston,
Massachusetts
|
+$434K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$415K |
| 4 |
Pinnacle Associates
New York
|
+$269K |
| 5 |
BlackRock
New York
|
+$178K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Silverarc Capital Management
Boston,
Massachusetts
|
-$350K |
| 2 |
Interchange Capital Partners
Pittsburgh,
Pennsylvania
|
-$102K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$99K |
| 4 |
DLG
Daniel L. Goodwin
|
-$78.5K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$34.4K |
ATNM Hedge Fund Activity: Q2 2021 in Review
37 of the 5,770 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2021, worth a combined $13.7M — up 37% from $10M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATNM and 4 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 15 added.
The largest buyer was Vanguard Group, adding an estimated $1.94M. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $350K sold.
- 37 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2021, down from 40 in Q1 2021.
- Funds reported $13.7M of Actinium Pharmaceuticals stock for Q2 2021, up 37% quarter-over-quarter.
- 4 funds opened new Actinium Pharmaceuticals positions in Q2 2021 and 7 closed out, a net change of -3 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $1.94M added.
- The largest Actinium Pharmaceuticals seller in Q2 2021 was Silverarc Capital Management, an estimated $350K sold.
Based on aggregated 13F filings for Q2 2021.